Raichur (Karnataka) [India], August 28: In a major breakthrough, Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) proudly announces the successful completion of its Phase 1 clinical trial for its flagship product, sRbumin® - recombinant human albumin® 20% (rHA), becoming the